European Medicines Agency recommends authorisation of Nuvaxovid Covid-19 vaccine for adolescents aged 12 to 17

The European CHMP has recommended an extension of indication to include use in adolescents aged 12-17 years (currently approved in adults only). This is based on a study which showed the immune response in this age group was comparable to that seen in 18-25 year olds.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news